Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: A phase 1 study

Blood

Volumn 109, Issue 7, 2007, Pages 2999-3006

  Kornblau, Steven M ^a,b   Banker, Deborah E ^c   Stirewalt, Derek ^c   Shen, Danny ^c   Lemker, Elizabeth ^a   Verstovsek, Srdan ^b   Estrov, Zeev ^b   Faderl, Stefan ^b   Cortes, Jorge ^b   Beran, Miloslav ^b   Jackson, C Ellen ^a   Chen, Wenjing ^a   Estey, Elihu ^b   Appelbaum, Frederick R ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CHOLESTEROL; CYTARABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; PRAVASTATIN; PREDNISONE; RASBURICASE; UBIDECARENONE; VORICONAZOLE;

ACIDOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALKALINIZATION; ARTICLE; BLEEDING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; COLITIS; CONFUSION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; KIDNEY FAILURE; LIPID METABOLISM; LOADING DRUG DOSE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYOPATHY; NAUSEA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SEIZURE; SIDE EFFECT; SYNCOPE; THROMBOSIS; TREATMENT OUTCOME; VOMITING;

EID: 33947594969     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-044446     Document Type: Article

References (20)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
2. Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood. 1994;84:2689-2698.
3. Banker DE, Mayer SJ, Li HY, et al. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood. 2004;104:1816-1824.
4. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2003;101:3628-3634.
5. Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, Banker DE. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res. 2003;27:133-145.
6. Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood. 1999;93:1308-1318.
7. Xia Z, Tan MM, Wong WW, et al. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia. 2001;15:1398-1407.
8. Newman A, Clutterbuck RD, Powles RL, Catovsky D, Millar JL. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma. 1997;24:533-537.
9. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98:3575-3583.
10. Hardmann JG, Limbird LE. Goodman and Gilman's the pharmacologic basis of therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001
11. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Can Res. 1996;2:483-491.
12. Sifton DW. Physician's desk reference. 56th ed. Montvale, NJ: Medical Economics Company; 2002.
13. Schiffer CA, Lee E, Tomiyasu T, Wiernik P, Testa J. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73:263-270.
14. Keating MJ, Cork A, Broach Y, et al. Toward a clinically relevant cytogenetic classification of AML. Leuk Res. 1987;11:119-133.
15. Estey EH, Kornblau S, Pierce S, et al. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996;88:756.
16. Jones PH, Farmer JA, Cressman MD, et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol. 1991;14:146-151.
17. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
18. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001;84:886-891.
19. Larner J, Jane J, Laws E, et al. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol. 1998;21:579-583.
20. Demierre M-F, Higgins PDR, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930-942.